big bang factory is happy to share the great news! We have been lucky enough to work with IMMR on their go-to-market strategy and help them find a cost-effective way to launch in the US. 

Veranex, the first concept-to-commercialization global service provider dedicated to the MedTech industry, today announced the acquisition of IMMR, a leading preclinical science organization that provides preclinical research, pathology evaluation, and surgical training services to medical technology innovators. IMMR is located in Paris, France.

Formed in June 2021 with global growth investor Summit Partners, Veranex provides the global medical technology industry with comprehensive and integrated solutions and services that accelerate the product life cycle to help improve the lives of patients everywhere. 

IMMR’s unique, highly efficient, and full-service approach — with studies that are carefully planned, expertly conducted to the highest ethical standards, and professionally documented —saves money and reduces time to market.

As a result of this acquisition, Veranex gains state-of-the-art, FDA-inspected, and AAALAC-accredited facilities and extensive in-house expertise, enhancing Veranex’s services for preclinical studies worldwide. 

“Veranex’s clients will benefit from IMMR’s 30 plus years of experience in the design and conduct of preclinical studies, expertise in complex cardiovascular and non-cardiovascular procedures, and state-of-the-art surgical suites and husbandry facilities, all unparalleled for leading successful completion of sophisticated studies with novel interventional or surgical technologies,” said Patrick K. Donnelly, Executive Chairman at Veranex.

For this transaction, financial advisors were Clearwater International and Cain Brothers, a division of KeyBanc Capital Markets, and Gide Loyrette Nouel, a leading international law firm located in Paris, who served as legal counsel.